Summit Trail Advisors LLC Sells 116 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Summit Trail Advisors LLC lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 3,814 shares of the medical equipment provider’s stock after selling 116 shares during the period. Summit Trail Advisors LLC’s holdings in Intuitive Surgical were worth $1,287,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. WCM Investment Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $575,536,000. International Assets Investment Management LLC increased its holdings in shares of Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd raised its position in shares of Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after acquiring an additional 677,455 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Intuitive Surgical during the third quarter valued at $178,667,000. Finally, Quadrature Capital Ltd boosted its holdings in Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after acquiring an additional 280,480 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded up $1.69 during midday trading on Monday, reaching $383.05. The company had a trading volume of 878,161 shares, compared to its average volume of 1,616,046. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The stock has a fifty day moving average price of $385.40 and a 200 day moving average price of $350.34. The firm has a market cap of $135.87 billion, a PE ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the transaction, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. Over the last quarter, insiders sold 228,637 shares of company stock valued at $88,483,248. Company insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on ISRG. Stifel Nicolaus upped their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Jefferies Financial Group upped their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Royal Bank of Canada increased their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Finally, StockNews.com lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.